Table 3. Comparison of the clinical characteristics and IHC scores between the MPR and non-MPR groups.
| Variables | Non-MPR | MPR | P |
|---|---|---|---|
| Patients | 10 | 13 | |
| Age | 63.2±4.4 | 63.2±8.7 | 0.828 |
| Gender | |||
| Male, n (%) | 10 (100.0) | 12 (92.3) | |
| Female | 0 | 1 (7.7) | 1.000 |
| Smoking history, n (%) | |||
| No | 2 (20.0) | 7 (53.8) | |
| Yes | 8 (80.0) | 6 (46.2) | 0.197 |
| Treatment cycles, n (%) | |||
| 2 | 6 (60.0) | 9 (69.2) | |
| >2 | 4 (40.0) | 4 (30.8) | 0.685 |
| Adverse effect, n (%) | |||
| No | 3 (30.0) | 3 (23.1) | |
| Yes | 7 (70.0) | 10 (76.9) | 1.000 |
| Pretreatment PD-L1 expression, n (%) | |||
| Negative | 3 (30.0) | 5 (38.4) | |
| Positive | 3 (30.0) | 4 (30.8) | |
| NA | 4 (40.0) | 4 (30.8) | 1.000 |
| Pathology, n (%) | |||
| Squamous cell carcinoma | 7 (70.0) | 11 (84.6) | |
| Adenocarcinoma | 3 (30.0) | 0 (7.7) | |
| Non-small cell lung cancer | 0 | 2 (15.4) | 0.024 |
| Clinical stage, n (%) | |||
| II | 2 (20.0) | 0 | |
| III | 8 (80.0) | 13 (100.0) | 0.178 |
| Radiological response, n (%) | |||
| SD | 4 (40.0) | 0 | |
| PR | 6 (60.0) | 8 (61.5) | |
| CR | 0 | 5 (38.5) | 0.002 |
| Postoperative IHC score | |||
| CD4 | 16.5±7.5 | 22.3±17.3 | 0.723 |
| CD8 | 21.6±16.5 | 30.2±30.5 | 0.661 |
| CD20 | 56.1±36.8 | 81.5±49.4 | 0.189 |
| PD-1 | 14.6±18.7 | 2.8±2.9 | 0.080 |
| PD-L1 | 9.5±20.0 | 2.3±4.7 | 1.000 |
| TIM3 | 0.6±1.3 | 3.5±8.5 | 0.925 |
| FXOP3 | 3.5±4.5 | 3.9±8.0 | 0.563 |
| LAG3 | 2.0±6.3 | 0 | 0.146 |
| TIGIT | 6.8±7.9 | 3.4±3.4 | 0.552 |
IHC, immunohistochemistry; MPR, major pathologic response; PD-L1, programmed cell death ligand 1; NA, not available; SD, stable disease; PR, partial response; CR, complete response; CD, cluster of differentiation; PD-1, the programmed cell death receptor 1; TIM3, T cell immunoglobulin mucin 3; FXOP3, mouse fork head Box Protein P 3; LAG3, lymphocyte-activation gene 3; TIGIT, T cell immunoglobulin and ITIM domain.